Smith & Nephew Advanced Wound Management Expands Presence at the Symposium on Advanced Wound Care

News provided by

Smith & Nephew

Apr 29, 2015, 09:00 ET

FORT WORTH, Texas, April 29, 2015 /PRNewswire/ -- Smith & Nephew (LSE: SN,NYSE: SNN), the global medical technology business, announced today that 24 company-sponsored posters and symposia will be presented at the 2015 Symposium on Advanced Wound Care (SAWC) Annual Meeting which begins today in San Antonio, Texas.

"As a member of the global wound care community for more than 150 years, Smith & Nephew is committed to advancing the scientific basis for innovative management of serious, chronic and acute wounds," said Jaime Dickerson, PhD, Vice President of Global Medical & Clinical Affairs at Smith & Nephew's Advanced Wound Management division. "We present our science at SAWC because of our commitment to evidence-based medicine and the platform for thought leadership which SAWC provides."

The following Smith & Nephew-sponsored data will be presented via an oral session at the 2015 SAWC Annual Meeting:

  • Oral Presentation (session 27): A Randomized, Open Label, Controlled Trial of a Tri-Layer Extracellular Matrix vs. Standard Care in the Healing of Diabetic Foot Ulcers; Abstract #CR-005: Friday, May 1, 2015; 10:30 – 11:30 AM CT (also presented via poster presentation at times listed below)

The following Smith & Nephew-sponsored data will be presented via poster presentation at the 2015 SAWC Annual Meeting on Friday, May 1 and Saturday, May 2 from 7:30 AM – 6:00 PM CT:

  • Poster Presentation (#CS-003): Antibiofilm Efficacy of a Silver HydrofiberTM Antibiofilm Dressing and Cadexomer Iodine Dressing on Mature Biofilms
  • Poster Presentation (#CS-009): Use of a Comprehensive Pressure Ulcer Prevention Program to Reduce the Incidence of Hospital-acquired Pressure Ulcers in an Intensive Care Unit Setting
  • Poster Presentation (#CS-017): Preventing Wound Dehiscence and Surgical Site Infections Using Single Use Negative Pressure Therapy System in Post-Op C-Section Patients with BMI >35
  • Poster Presentation (#CS-018): A Prospective, Randomised, Intra-Patient, Comparative, Open, Multi-Centre Study to Evaluate the Efficacy of a Single-Use Negative Pressure Wound Therapy (NPWT) System on the Prevention of Post-surgical Incision Healing Complications in Patients Undergoing Bilateral Breast Surgery
  • Poster Presentation (#CS-019): The Management of a Dehisced Surgical Wound in a Pregnant Lady Using a New Portable Negative Pressure Wound Therapy (NPWT) Device
  • Poster Presentation (#CS-020): An Evaluation of a Portable Single Use Negative Pressure Wound Therapy (NPWT) Dressing to Reduce Wound Complications in Paediatric Spinal Surgery
  • Poster Presentation (#CS-021): Single Use Negative Pressure Wound Therapy (suNPWT) System for Wound Healing in an Outpatient Clinic
  • Poster Presentation (#CS-022): Pressure Ulcer Prevention: Use of Prophylactic Multilayer Adhesive Foam Dressings in Intensive Care Unit
  • Poster Presentation (#CS-024): Portable Topical Negative Pressure: Evaluation in Venous Ulcers and Skin Grafts
  • Poster Presentation (#IR-005): Pharmacoepidemiology of Clostridial Collagenase Ointment for the Treatment of Pressure Ulcers in Outpatient Care Settings
  • Poster Presentation (#IR-006): Pharmacoepidemiology of Clostridial Collagenase Ointment for the Treatment of Venous Leg Ulcers in Outpatient Care Settings
  • Poster Presentation (#IR-007): Pharmacoepidemiology of Cellular/Tissue Derived Products for the Treatment of Diabetic Foot Ulcers in Outpatient Care Settings
  • Poster Presentation (#IR-008): Pharmacoepidemiology of Clostridial Collagenase Ointment for the Treatment of Diabetic Foot Ulcers in Outpatient Care Settings
  • Poster Presentation (#IR-009): Epidemiology of Advanced Therapies for the Treatment of Diabetic Foot Ulcers in Outpatient Care Settings
  • Poster Presentation (#IR-025): Improving Efficiency in Wound Care Through the Introduction of a New Foam Dressing
  • Poster Presentation (#P.BW06): Quantifying the Costs Savings of Two Commonly Used Silver Dressings in Patients With Deep Partial Thickness Burns
  • Poster Presentation (#P.CW17): A Probabilistic Cost Effectives Analysis of Cadexomer Iodine Ointment Plus Standard Care Compared to Standard Care Alone in Chronic Venous Leg Ulcers

In addition, the following complementary accredited symposia will be offered in conjunction with the 2015 SAWC Annual Meeting:

  • Interactive Educational Session: Debridement Across the Continuum of Care and Economic Insights; Thursday, April 30, 2015; 8:00 – 9:00 AM CT; registration required
  • Interactive Educational Session: Diabetes and Wound Health Pathophysiology: Regulating Wound Healing by Growth Factors; Friday, May 1, 2015; 8:00 – 9:00 AM CT; registration required

Lastly, the following company-sponsored symposia (non-accredited) will be offered in conjunction with the 2015 SAWC Annual Meeting:

  • Symposium: Use of Collagenase SANTYL® Ointment in Wound Bed Preparation; Wednesday, April 29; 6:00 – 7:30 PM CT; registration required
  • Symposium: Diabetic Neuropathic Ulcers – Recognizing the Significant Burden and Reviewing a Treatment Option; Thursday, April 30; 12:30 – 2:00 PM CT; registration required
  • Symposium: Driving to Zero: Reducing Hospital-acquired Pressure Ulcers in the OR and ICU; Thursday, April 30; 12:30 – 2:00 PM CT; registration required

About Smith & Nephew Advanced Wound Management

With an entire portfolio of wound management products, Smith & Nephew AWM is committed to understanding and treating the tremendous burden of chronic wounds—which is estimated at $33 billion per year in the U.S.—with evidence-based medical solutions including:

  • ACTICOAT™ – a proprietary silver-coated dressing that provides powerful bactericidal activity. ACTICOAT helps kill a broad spectrum of pathogens, is fast acting and provides long lasting, sustained release efficacy.
  • ALLEVYN™ Life – a unique five-layer hydrocellular foam dressing that provides an all-in-one option for both wound management and pressure ulcer prevention.
  • Collagenase SANTYL™ Ointment (250 units/gram) – the only FDA-approved prescription biologic product for enzymatic debridement indicated for debridement of chronic dermal ulcers and severely burned areas. It actively and selectively debrides necrotic tissue, without harming granulation tissue. Please see full prescribing information. Occasional slight transient erythema has been noted in surrounding tissue when applied outside the wound. One case of systemic hypersensitivity has been reported after one year of treatment with collagenase and cortisone. Use of Collagenase SANTYL Ointment should be terminated when debridement is complete and granulation tissue is well established.
  • IODOSORB™ – a unique Cadexomer Iodine technology that removes multiple barriers to healing in venous stasis ulcers.
  • OASIS® Ultra Tri-Layer Matrix – a porcine derived, intact, three-dimensional extra-cellular matrix that helps support the body's own tissue repair mechanisms.
  • PICO™ – an innovative technology that offers all of the effectiveness of traditional negative pressure wound therapy in an off-the-shelf, single use, canister-free system that can be used to simplify the management of open wounds and may help reduce the risk of surgical site complications.
  • REGRANEX™ (becaplermin) Gel, 0.01% – the first and only FDA-approved platelet derived growth factor prescription product proven to heal lower extremity diabetic neuropathic wounds, when used in conjunction with good ulcer care. Please see full prescribing information with boxed warning and Important Safety Information. WARNING: INCREASED RATE OF MORTALITY SECONDARY TO MALIGNANCY: An increased rate of mortality secondary to malignancy was observed in patients treated with three or more tubes of REGRANEX Gel in a postmarketing retrospective cohort study. REGRANEX Gel should only be used when the benefits can be expected to outweigh the risks. REGRANEX Gel should be used with caution in patients with known malignancy.
  • SECURA™ – a proven four-step preventive skin care system formulated with high quality, skin-friendly ingredients designed to protect the skin and prevent skin breakdown.
  • VERSAJET™ – a hydrosurgical system that enables a surgeon to precisely select, excise and evacuate nonviable tissue, bacteria and contaminants from wounds, burns and soft tissue injuries using a tissue-sparing technique.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 14,000 employees and a presence in more than 100 countries. Annual sales in 2014 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN,NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

Media Inquiries:
Christie Teller
817-905-7158
[email protected]

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
Oasis® is a registered trademark of Cook Biotech.

SOURCE Smith & Nephew

Related Links

http://www.smith-nephew.com